Jaffetilchin Investment Partners’s Quest Diagnostics DGX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-62	Closed	-$9.57K	–	586
2024 Q3	$9.57K	Buy	+62	New	+$9.26K	﹤0.01%	910
2020 Q3	–	Sell	-3,859	Closed	-$440K	–	230
2020 Q2	$440K	Buy	+3,859	New	+$409K	0.1%	131
2017 Q1	–	Sell	-2,320	Closed	-$213K	–	262
2016 Q4	$213K	Buy	+2,320	New	+$200K	0.06%	223
2015 Q3	–	Sell	-2,812	Closed	-$204K	–	192
2015 Q2	$204K	Buy	2,812 +1	+0%	+$74	0.06%	187
2015 Q1	$216K	Buy	+2,811	New	+$201K	0.07%	200
2014 Q4	–	Sell	-6,708	Closed	-$407K	–	202
2014 Q3	$407K	Buy	+6,708	New	+$413K	0.15%	113

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jaffetilchin Investment Partners's DGX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Quest Diagnostics (DGX) in Q4 2024, closing a stake of 62 shares — an estimated $9.57K sold.

Jaffetilchin Investment Partners first reported a position in DGX in Q3 2014 and held it in 6 quarters. The position peaked at $440K in Q2 2020. 896 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

Jaffetilchin Investment Partners reported no remaining Quest Diagnostics position as of Q4 2024 after selling out during the quarter.
Jaffetilchin Investment Partners sold 62 Quest Diagnostics shares in Q4 2024, an estimated $9.57K.
Jaffetilchin Investment Partners first reported a position in Quest Diagnostics in Q3 2014 and held it in 6 quarters.
Jaffetilchin Investment Partners's Quest Diagnostics position peaked at $440K in Q2 2020.
896 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.